Pular para o conteúdo
Doença granulomatosa crônica
ORPHA:379CID-10 · D71CID-11 · 4A00.0YDOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
DigestivoInício infânciaHerança AR/XL
Também conhecida comoCGDDGC

A Doença Granulomatosa Crônica (DGC) é uma imunodeficiência primária rara, que afeta principalmente os fagócitos (células de defesa do corpo). Ela se caracteriza por uma maior facilidade em desenvolver infecções graves e que se repetem, causadas por bactérias e fungos, além do surgimento de granulomas (pequenas inflamações ou nódulos).

Última verificação: Fonte: sem afirmação sobre o SUS a verificarEm construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

A doença granulomatosa crônica é um distúrbio que faz com que o sistema imunológico funcione de forma inadequada, resultando em uma forma de imunodeficiência. Imunodeficiências são condições nas quais o sistema imunológico não consegue proteger o corpo de invasores externos, como bactérias e fungos. Indivíduos com doença granulomatosa crônica podem ter infecções bacterianas e fúngicas recorrentes. Pessoas com essa condição também podem apresentar áreas de inflamação (granulomas) em vários tecidos, o que pode causar dano a esses tecidos. As características da doença granulomatosa crônica geralmente aparecem pela primeira vez na infância, embora alguns indivíduos não apresentem sintomas até mais tarde na vida.

Pessoas com doença granulomatosa crônica tipicamente apresentam pelo menos uma infecção bacteriana ou fúngica grave a cada 3 a 4 anos. Os pulmões são a área de infecção mais frequente; a pneumonia é uma característica comum dessa condição. Indivíduos com doença granulomatosa crônica podem desenvolver um tipo de pneumonia fúngica, chamada pneumonite por mulch (mulch pneumonitis), que causa febre e falta de ar após a exposição a materiais orgânicos em decomposição, como composto, feno ou folhas mortas. A exposição a esses materiais orgânicos e aos numerosos fungos envolvidos em sua decomposição faz com que pessoas com doença granulomatosa crônica desenvolvam infecções fúngicas nos pulmões. Outras áreas comuns de infecção em pessoas com doença granulomatosa crônica incluem a pele, o fígado e os linfonodos.

A inflamação pode ocorrer em muitas áreas diferentes do corpo em pessoas com doença granulomatosa crônica. Mais comumente, os granulomas aparecem no trato gastrointestinal e no trato geniturinário. Em muitos casos, a parede intestinal está inflamada, causando uma forma de doença inflamatória intestinal que varia em gravidade, mas pode levar a dor abdominal, diarreia, fezes com sangue, náuseas e vômitos. Outras áreas comuns de inflamação em pessoas com doença granulomatosa crônica incluem o estômago, o cólon e o reto, bem como a boca, a garganta e a pele. Além disso, os granulomas dentro do trato gastrointestinal podem levar à degradação do tecido e à produção de pus (abscessos). A inflamação no estômago pode impedir que o alimento passe para os intestinos (obstrução da saída gástrica), levando à incapacidade de digerir os alimentos. Esses problemas digestivos causam vômitos após as refeições e perda de peso. No trato geniturinário, a inflamação pode ocorrer nos rins e na bexiga. A inflamação dos linfonodos (linfadenite) e da medula óssea (osteomielite), que ambos produzem células imunológicas, pode levar a um comprometimento adicional do sistema imunológico.

Raramente, pessoas com doença granulomatosa crônica desenvolvem distúrbios autoimunes, que ocorrem quando o sistema imunológico funciona de forma inadequada e ataca os próprios tecidos e órgãos do corpo.

Episódios repetidos de infecção e inflamação reduzem a expectativa de vida de indivíduos com doença granulomatosa crônica; porém, com tratamento, a maioria das pessoas afetadas vive até a meia‑idade ou fase avançada da vida adulta.

Fonte: MedlinePlus Genetics (NLM/NIH), traduzido
📋
Informacoes curadas por IA — podem conter imprecisoes

A Doença Granulomatosa Crônica (DGC) é uma imunodeficiência primária rara, que afeta principalmente os fagócitos (células de defesa do corpo). Ela se caracteriza por uma maior facilidade em desenvolver infecções graves e que se repetem, causadas por bactérias e fungos, além do surgimento de granulomas (pequenas inflamações ou nódulos).

Pesquisas ativas
23 ensaios
77 total registrados no ClinicalTrials.gov
Publicações científicas
4.319 artigos
Último publicado: 2026 Apr
Medicamentos
1 com registro
ACTIMMUNE (INTERFERON GAMMA-1B)

Tem tratamento?

✓ 1 medicamento específico desta doença (registro ANVISA, FDA ou SUS/CEAF)
Ver detalhes, fases e interações →
ACTIMMUNE (INTERFERON GAMMA-1B)

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
Adolescent
+ adult, childhood, infancy
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: D71
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫃
Digestivo
11 sintomas
🫁
Pulmão
10 sintomas
🩸
Sangue
9 sintomas
🛡️
Imunológico
8 sintomas
🧬
Pele e cabelo
6 sintomas
🫘
Rins
2 sintomas

+ 34 sintomas em outras categorias

Características mais comuns

90%prev.
Mácula hiperpigmentada
Muito frequente (99-80%)
90%prev.
Infecções respiratórias recorrentes
Muito frequente (99-80%)
90%prev.
Má absorção
Muito frequente (99-80%)
90%prev.
Febre
Muito frequente (99-80%)
90%prev.
Sinusite
Muito frequente (99-80%)
90%prev.
Hepatomegalia
Muito frequente (99-80%)
84sintomas
Muito frequente (14)
Ocasional (8)
Sem dados (62)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 84 características clínicas mais associadas, ordenadas por frequência.

Mácula hiperpigmentadaHypermelanotic macule
Muito frequente (99-80%)90%
Infecções respiratórias recorrentesRecurrent respiratory infections
Muito frequente (99-80%)90%
Má absorçãoMalabsorption
Muito frequente (99-80%)90%
FebreFever
Muito frequente (99-80%)90%
SinusiteSinusitis
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico4.319PubMed
Últimos 10 anos200publicações
Pico2025107 papers
Linha do tempo
2026Hoje · 2026🧪 1991Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

6 genes identificados com associação a esta condição. Padrão de herança: Autosomal recessive, X-linked recessive.

NCF2Neutrophil cytosol factor 2Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (5)
RHO GTPases Activate NADPH OxidasesVEGFA-VEGFR2 PathwayRAC3 GTPase cycleRAC1 GTPase cycleDetoxification of Reactive Oxygen Species
MECANISMO DE DOENÇA

Granulomatous disease, chronic, autosomal recessive, 2

A form of chronic granulomatous disease, a primary immunodeficiency characterized by severe recurrent bacterial and fungal infections, along with manifestations of chronic granulomatous inflammation. It results from an impaired ability of phagocytes to mount a burst of reactive oxygen species in response to pathogens.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
639.6 TPM
Baço
104.7 TPM
Pulmão
89.4 TPM
Linfócitos
68.1 TPM
Adipose Visceral Omentum
17.8 TPM
OUTRAS DOENÇAS (2)
granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type 2chronic granulomatous disease
HGNC:7661UniProt:P19878
CYBC1Cytochrome b-245 chaperone 1Disease-causing germline mutation(s) (loss of function) inTolerante
MECANISMO DE DOENÇA

Granulomatous disease, chronic, autosomal recessive, 5

A form of chronic granulomatous disease, a primary immunodeficiency characterized by severe recurrent bacterial and fungal infections, along with manifestations of chronic granulomatous inflammation. It results from an impaired ability of phagocytes to mount a burst of reactive oxygen species in response to pathogens. CGD5 is an autosomal recessive form characterized by onset of recurrent infections and severe colitis in the first decade of life. Clinical manifestations include increased susceptibility to catalase-positive organisms, features of inflammatory bowel disease, lymphopenia, lymphadenitis, and autoinflammatory symptoms in some patients.

OUTRAS DOENÇAS (2)
granulomatous disease, chronic, autosomal recessive, 5chronic granulomatous disease
HGNC:28672UniProt:Q9BQA9
CYBACytochrome b-245 light chainDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (6)
RHO GTPases Activate NADPH OxidasesVEGFA-VEGFR2 PathwayRAC3 GTPase cycleRAC1 GTPase cycleNeutrophil degranulation
MECANISMO DE DOENÇA

Granulomatous disease, chronic, autosomal recessive, 4

A form of chronic granulomatous disease, a primary immunodeficiency characterized by severe recurrent bacterial and fungal infections, along with manifestations of chronic granulomatous inflammation. It results from an impaired ability of phagocytes to mount a burst of reactive oxygen species in response to pathogens.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
448.9 TPM
Baço
351.6 TPM
Linfócitos
172.3 TPM
Pulmão
136.9 TPM
Intestino delgado
107.6 TPM
OUTRAS DOENÇAS (2)
granulomatous disease, chronic, autosomal recessive, cytochrome b-negativechronic granulomatous disease
HGNC:2577UniProt:P13498
NCF4Neutrophil cytosol factor 4Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (5)
RHO GTPases Activate NADPH OxidasesVEGFA-VEGFR2 PathwayRAC3 GTPase cycleRAC1 GTPase cycleDetoxification of Reactive Oxygen Species
MECANISMO DE DOENÇA

Granulomatous disease, chronic, autosomal recessive, 3

A form of chronic granulomatous disease, a primary immunodeficiency characterized by severe recurrent bacterial and fungal infections, along with manifestations of chronic granulomatous inflammation. It results from an impaired ability of phagocytes to mount a burst of reactive oxygen species in response to pathogens.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
592.6 TPM
Baço
214.0 TPM
Pulmão
70.3 TPM
Linfócitos
47.7 TPM
Intestino delgado
41.9 TPM
OUTRAS DOENÇAS (2)
granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type 3chronic granulomatous disease
HGNC:7662UniProt:Q15080
CYBBNADPH oxidase 2Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (5)
RHO GTPases Activate NADPH OxidasesVEGFA-VEGFR2 PathwayRAC3 GTPase cycleRAC1 GTPase cycleNeutrophil degranulation
MECANISMO DE DOENÇA

Granulomatous disease, chronic, X-linked

A form of chronic granulomatous disease, a primary immunodeficiency characterized by severe recurrent bacterial and fungal infections, along with manifestations of chronic granulomatous inflammation. It results from an impaired ability of phagocytes to mount a burst of reactive oxygen species in response to pathogens.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
93.5 TPM
Baço
87.0 TPM
Linfócitos
56.1 TPM
Pulmão
48.5 TPM
Intestino delgado
22.5 TPM
OUTRAS DOENÇAS (4)
X-linked Mendelian susceptibility to mycobacterial diseases due to CYBB deficiencygranulomatous disease, chronic, X-linkedX-linked Mendelian susceptibility to mycobacterial diseaseschronic granulomatous disease
HGNC:2578UniProt:P04839
NCF1Neutrophil cytosol factor 1Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (5)
RHO GTPases Activate NADPH OxidasesVEGFA-VEGFR2 PathwayRAC3 GTPase cycleRAC1 GTPase cycleDetoxification of Reactive Oxygen Species
MECANISMO DE DOENÇA

Granulomatous disease, chronic, autosomal recessive, 1

A form of chronic granulomatous disease, a primary immunodeficiency characterized by severe recurrent bacterial and fungal infections, along with manifestations of chronic granulomatous inflammation. It results from an impaired ability of phagocytes to mount a burst of reactive oxygen species in response to pathogens.

EXPRESSÃO TECIDUAL(Tecido-específico)
Sangue
186.0 TPM
Linfócitos
163.1 TPM
Baço
72.0 TPM
Pulmão
14.3 TPM
Intestino delgado
11.1 TPM
OUTRAS DOENÇAS (3)
granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type 1Williams syndromechronic granulomatous disease
HGNC:7660UniProt:P14598

Medicamentos aprovados (FDA)

1 medicamento encontrado nos registros da FDA americana.

💊 ACTIMMUNE (INTERFERON GAMMA-1B)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

322 variantes patogênicas registradas no ClinVar.

🧬 NCF2: NM_000433.4(NCF2):c.174+1G>A ()
🧬 NCF2: NM_000433.4(NCF2):c.367-1G>C ()
🧬 NCF2: NM_000433.4(NCF2):c.584dup (p.Lys196fs) ()
🧬 NCF2: NM_000433.4(NCF2):c.924+2T>C ()
🧬 NCF2: NM_000433.4(NCF2):c.1274G>A (p.Trp425Ter) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 195 variantes classificadas pelo ClinVar.

10
175
10
Patogênica (5.1%)
VUS (89.7%)
Benigna (5.1%)
VARIANTES MAIS SIGNIFICATIVAS
CYBA: NC_000016.9:g.(?_88709696)_(88717462_?)del [Pathogenic]
CYBB: NM_000397.4(CYBB):c.805-4del [Uncertain significance]
CYBB: NM_000397.4(CYBB):c.617G>T (p.Trp206Leu) [Uncertain significance]
CYBB: NM_000397.4(CYBB):c.1634C>T (p.Thr545Ile) [Uncertain significance]
CYBB: NM_000397.4(CYBB):c.1600G>A (p.Val534Ile) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
✓Aprovado2
3Fase 33
2Fase 237
1Fase 114
·Pré-clínico21
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 77 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença granulomatosa crônica

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 8 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

16 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT07826767 · Open-label Gene Therapy Study in p47-CGDRecrutando
PHASE1, PHASE2🇩🇪 Alemanha · 🇪🇸 Espanha · 🇨🇭 Suíça
NCT07284641 · Hematopoietic Stem Cell Transplantation (HSCT) for Common Va…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT06605378 · Prevalence of Antibodies and Cytokines in Participants With …Recrutando
🇬🇧 Reino Unido · 🇺🇸 Estados Unidos
NCT06325709 · Base Editing for Mutation Repair in Hematopoietic Stem & Pro…Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT05333471 · Fecal Microbiota Transplantation for Chronic Granulomatous D…Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT05189925 · NADPH Oxidase Correction in mRNA-transfected Granulocyte-enr…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT05463133 · Allogeneic Hematopoietic Stem Cell Transplantation for Chron…Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT04528355 · Data Collection Study of Patients With Non-Malignant Disorde…Recrutando
🇺🇸 Estados Unidos
NCT03055247 · Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells…Recrutando
PHASE2🇮🇹 Itália
NCT01962415 · Reduced Intensity Conditioning for Non-Malignant Disorders U…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT00128973 · Evaluation of Patients With Immune Function AbnormalitiesRecrutando
🇺🇸 Estados Unidos
NCT00001405 · Recruitment and Apheresis Collection of Peripheral Blood Hem…Recrutando
🇺🇸 Estados Unidos
NCT07113743 · Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) i…Por convite
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT06559176 · A Study of the Safety and Efficacy of Prime Editing (PM359) …Por convite
PHASE1, PHASE2🇨🇦 Canadá · 🇬🇧 Reino Unido · 🇺🇸 Estados Unidos
NCT06253507 · pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) …Por convite
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT01852370 · Sequential Cadaveric Lung and Bone Marrow Transplant for Imm…Por convite
PHASE1, PHASE2🇺🇸 Estados Unidos

Outros ensaios clínicos

77 ensaios clínicos encontrados, 23 ativos.

Distribuição por fase
NCT03645486 · Lentiviral Gene Therapy for CGDEm breve
NA🇨🇳 China
NCT06876363 · Study of EN-374 Gene Therapy in Participants With X-Linked C…Ativo
PHASE1, PHASE2🇬🇧 Reino Unido · 🇺🇸 Estados Unidos
NCT05600907 · Study to Assess the Use of JSP191 in Matched Unrelated Donor…Ativo
EARLY_PHASE1🇺🇸 Estados Unidos
NCT03910452 · Haploidentical Transplant for People With Chronic Granulomat…Ativo
EARLY_PHASE1🇺🇸 Estados Unidos
NCT02629120 · High Dose Peripheral Blood Stem Cell Transplantation With Po…Ativo
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT01821781 · Immune Disorder HSCT ProtocolAtivo
PHASE2🇺🇸 Estados Unidos
NCT01652092 · Allogeneic Hematopoietic Stem Cell Transplant for Patients W…Ativo
NA🇺🇸 Estados Unidos
NCT05104723 · Safety and Efficacy of Tofacitinib for Chronic Granulomatous…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT03983837 · Elemental Diet for Treatment of Inflammatory Bowel Disease i…Concluído
PHASE2🇺🇸 Estados Unidos
NCT03984890 · Vitamin D3 For CGD Patients With BCGosis/ItisConcluído
PHASE2, PHASE3🇨🇳 China
NCT03513328 · Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell …Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT03548818 · Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate …Concluído
🇺🇸 Estados Unidos
NCT02609932 · Effect of IFN-γ on Innate Immune CellsConcluído
PHASE1🇺🇸 Estados Unidos
NCT02234934 · Study of Gene Therapy Using a Lentiviral Vector to Treat X-l…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT04136028 · IL-1 Receptor Inhibitor for Granulomatous Complications in P…Concluído
EARLY_PHASE1Russia
NCT02116764 · Analysis of Patients Treated for Chronic Granulomatous Disea…Concluído
🇺🇸 Estados Unidos
NCT02108028 · Study of Voicing My CHOiCES as a Tool for Advanced Care Plan…Concluído
🇺🇸 Estados Unidos
NCT01917708 · Bone Marrow Transplant With Abatacept for Non-Malignant Dise…Concluído
PHASE1🇺🇸 Estados Unidos
NCT01998633 · Reduced Intensity Conditioning for Hemophagocytic Syndromes …Concluído
PHASE2🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT01063309 · Non-Invasive Assessment of Atherosclerosis in Patients With …Concluído
🇺🇸 Estados Unidos
NCT00799071 · Pharmacokinetics of Posaconazole in Children With Chronic Gr…Concluído
PHASE2🇳🇱 Países Baixos
NCT00730314 · Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for …Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT00368446 · Genetic Disorders of Mucociliary Clearance in Nontuberculous…Concluído
🇺🇸 Estados Unidos
NCT00092937 · Use of Busulfan as Conditioning Agent for a Second Stem Cell…Concluído
PHASE1🇺🇸 Estados Unidos
NCT00927134 · Gene Therapy for X-linked Chronic Granulomatous Disease (CGD…Concluído
PHASE1, PHASE2🇨🇭 Suíça
NCT00578643 · Matched Unrelated or Non-Genotype Identical Related Donor Tr…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00033982 · Posaconazole to Treat Invasive Fungal InfectionsConcluído
PHASE3🇺🇸 Estados Unidos
NCT00023192 · Treatment of Chronic Granulomatous Disease With Allogeneic S…Concluído
PHASE3🇺🇸 Estados Unidos
NCT00010361 · Study of Total Body Irradiation and Fludarabine Followed By …Concluído
NA🇺🇸 Estados Unidos
NCT00006417 · Modified Stem Cell Transplantation Procedure for Treating Ch…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00005933 · Learning and Behavior Problems in Children With Chronic Gran…Concluído
🇺🇸 Estados Unidos
NCT00001765 · Stem Cell Transplant Following Low-Intensity Chemotherapy to…Concluído
PHASE1🇺🇸 Estados Unidos
NCT00001515 · Diagnostic Effectiveness of Virtual BronchoscopyConcluído
PHASE1🇺🇸 Estados Unidos
NCT00001476 · Gene Therapy for Chronic Granulomatous Diseases - Long-term …Concluído
PHASE1🇺🇸 Estados Unidos
NCT00001317 · A Phase IV Study of Recombinant Human Gamma Interferon in Pa…Concluído
PHASE4🇺🇸 Estados Unidos
NCT00001280 · Itraconazole for the Prevention of Fungal Infections in Chro…Concluído
PHASE2🇺🇸 Estados Unidos
NCT06162936 · Neutrophil Oxidative Burst in Early and Late Onset Pediatric…UNKNOWN
Romania
NCT03547830 · Plerixafor/G-CSF as Additional Agents for Conditioning Befor…UNKNOWN
PHASE2Russia
NCT02231996 · Chronic Granulomatous Disease Study in ChinaUNKNOWN
🇨🇳 China
NCT02082353 · Patients Treated for Chronic Granulomatous Disease (CGD) Sin…UNKNOWN
🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT01906541 · Gene Therapy for X-CGDUNKNOWN
PHASE1, PHASE2🇩🇪 Alemanha
NCT01338675 · Targeted Busulfan, Fludarabine Conditioning Regimen for Hema…UNKNOWN
PHASE1, PHASE2South Korea
NCT00564759 · Gene Therapy for Chronic Granulomatous DiseaseUNKNOWN
PHASE1, PHASE2🇩🇪 Alemanha
NCT05915897 · Whole Blood Biospecimen Collection for Subjects With Chronic…Encerrado
🇺🇸 Estados Unidos
NCT03080480 · Pioglitazone Therapy for Chronic Granulomatous DiseaseEncerrado
PHASE1, PHASE2🇨🇳 China
NCT02231710 · Safety Study of Gene Modified Donor T Cell Infusion After St…Encerrado
PHASE1🇺🇸 Estados Unidos
NCT02282904 · Haploidentical Transplant for People With Chronic Granulomat…Encerrado
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT01855685 · Gene Therapy for X-linked Chronic Granulomatous Disease (X-C…Encerrado
PHASE1, PHASE2🇬🇧 Reino Unido
NCT02757911 · Gene Therapy for X-linked Chronic Granulomatous DiseaseEncerrado
PHASE1, PHASE2🇫🇷 França
NCT02926963 · Generation of Powerful Biological Tools for Understanding th…Encerrado
NA🇫🇷 França
NCT01319851 · Alefacept and Allogeneic Hematopoietic Stem Cell Transplanta…Encerrado
NA🇺🇸 Estados Unidos
NCT01147042 · Biochemical Response to Interferon-Gamma in Subjects With Sp…Encerrado
PHASE4🇺🇸 Estados Unidos
NCT02512679 · Related Hematopoietic Stem Cell Transplantation (HSCT) for G…Encerrado
PHASE2
NCT00394316 · Gene Therapy for Chronic Granulomatous DiseaseEncerrado
EARLY_PHASE1🇺🇸 Estados Unidos
NCT00325078 · Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease …Encerrado
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT00006054 · Allogeneic Bone Marrow Transplantation in Patients With Prim…Encerrado
NA🇺🇸 Estados Unidos
NCT03921515 · Skin Immunity Sample Collection Involving Blisters and Biops…Cancelado
EARLY_PHASE1🇺🇸 Estados Unidos
NCT03278912 · Natural History of Intestinal Inflammation in People With Pr…Cancelado
🇺🇸 Estados Unidos
NCT01851460 · Radiofrequency Ablation for Liver Abscesses From Chronic Gra…Cancelado
PHASE1🇺🇸 Estados Unidos
NCT01381003 · Lentiviral Gene Therapy for X-Linked Chronic Granulomatous D…Cancelado
PHASE1, PHASE2🇬🇧 Reino Unido
NCT00778882 · Gene Therapy for Chronic Granulomatous Disease in KoreaCancelado
PHASE1, PHASE2South Korea
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
1.331 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 1.331

#1

Excellent Outcome of 1-Day Nonmyeloablative Salvage Regimen for Pediatric Patients with Graft Failure following Haploidentical Hematopoietic Stem Cell Transplantation.

Transplantation and cellular therapy2026 Feb

Haploidentical (haplo-) hematopoietic stem cell transplantation (HSCT) has been increasingly used as an alternative transplantation strategy for patients lacking a suitable HLA-matched donor. T cell depletion reduces the risk of graft-versus-host disease (GVHD) but at a cost of increased risk of graft failure, necessitating immediate retransplantation if a cryopreserved autologous graft is not available for rescue. Traditional high-intensity reconditioning with myeloablative and immunoablative regimens of approximately 1 week's duration aimed at further suppressing the recipient-derived immune system capable of rejecting the primary graft, is associated with high morbidity and mortality. A shortened and reduced-intensity conditioning regimen might reduce infection risk and mortality, but sustained engraftment would be a concern with lowered intensity. Here we report the excellent outcomes of 11 pediatric patients who received a 1-day reduced-intensity preparative regimen prior to retransplantation for graft failure following initial myeloablative haplo-HSCT for various malignant and nonmalignant disease conditions. This was a retrospective study conducted at the Hong Kong Children's Hospital, the sole territory-wide pediatric HSCT center in Hong Kong. All pediatric patients who were age ≤18 years at the time of initial haplo-HSCT and subsequently underwent salvage haplo-HSCT with a 1-day nonmyeloablative salvage regimen owing to graft failure between June 1, 2021, and May 31, 2024, were included. The salvage regimen consisted of fludarabine (30 mg/m2), cyclophosphamide (2000 mg/m2 or 60 mg/kg), and alemtuzumab (0.3 mg/kg), with or without total body irradiation (2 Gy), all administered 1 day before retransplantation. G-CSF-mobilized peripheral blood stem cells (PBSCs) were collected and transplanted fresh without ex vivo T cell depletion whenever possible, while cryopreserved PBSCs were used if fresh apheresis was not possible. GVHD prophylaxis consisted of cyclosporine, mycophenolate mofetil, tacrolimus, or sirolimus. A total of 11 patients were recruited, including 9 males and 2 females, with a median age of 8.8 years (range, 2.4 to 17.5 years). Underlying diseases included transfusion-dependent anemias (n = 7; beta-thalassemia major = 4, hemoglobin Hammersmith = 1, pyruvate kinase deficiency = 1, severe aplastic anemia = 1), chronic granulomatous disease (n = 1), acute lymphoblastic leukemia (n = 1), post-liver transplant lymphoproliferative disease (n = 1) and neuroblastoma (n = 1). The median interval between haplo-HSCT and administration of the 1-day regimen was 26 days (range, 18 to 50 days). Fresh PBSC grafts were used in 9 patients, and cryopreserved PBSC grafts were used in 2 patients. Median cell viability was 99.6%, with a median stem cell dose of 7.2 × 106 CD34+ cells/kg (range, 4.81 to 20.6 × 106 cells/kg) and a median total nucleated cell (TNC) dose of 8.0 × 108/kg (range, 5.17 to 10 × 108/kg). All 9 patients with fresh PBSC grafts demonstrated sustained engraftment and hematopoietic recovery. The median times to neutrophil and platelet engraftment were day +12 (range, days 10 to 19) and day +16 (range, days 10 to 35), respectively. No patient developed grade III/IV acute GVHD or severe chronic GVHD. Both patients with cryopreserved PBSC grafts experienced another graft failure, but 1 of them was successfully salvaged with another 1-day regimen using a fresh PBSC graft, and the other had autologous regeneration and underwent successful haplo-HSCT again from the same donor after full myeloablative conditioning. Overall survival for all 11 patients was 100% at a median follow-up of 35 months (range, 18 to 52 months). To conclude, local experience suggests that the modified 1-day reduced-intensity regimen in combination with fresh but not cryopreserved PBSC grafts is a feasible and promising approach to achieving sustained engraftment and is safe and appropriate for salvaging pediatric patients with graft failure requiring immediate retransplantation.

#2

Umbilical Cord Blood Transplantation Provides an Alternative for Patients With Chronic Granulomatous Disease Lacking HLA-Matched Donors: A PIDTC Report.

Transplantation and cellular therapy2026 Jan

Allogeneic hematopoietic cell transplantation corrects the phagocytic defect in patients with chronic granulomatous disease (CGD) and resolves infection risk and immune dysregulation. Umbilical cord blood transplantation (UCBT) is an option for patients lacking suitable HLA-matched bone marrow or peripheral blood stem cell donors. However, information related to UCBT for CGD is limited to a few small case series and limited subsets of larger cohorts where detailed information is lacking. To describe UCBT procedures and outcomes in patients with CGD. Thirty-nine patients with CGD who underwent UCBT at Primary Immune Deficiency Treatment Consortium (PIDTC) centers between 2001 and 2019 were included. All patients were male, and most (97%) had X-linked CGD due to pathogenic variants in CYBB. High infection burden (1.72/person years) and inflammatory disease (38%) were common in the year pre-UCBT. Median age at receipt of UCBT was 2.1 (range 0.3-14.0) years. Most (87%) patients received UCB from unrelated donors, and most (72%) patients received busulfan and cyclophosphamide-based conditioning. All but two (95%) patients received serotherapy with anti-thymocyte globulin or alemtuzumab. Neutrophil and platelet recovery occurred at a median of 18 (range 12-46) and 38 (range 21-186) days, respectively. Nine patients experienced early graft failure [donor myeloid chimerism <10% or receipt of second hematopoietic cell transplantation (HCT) within 100 days] for a cumulative incidence of 23.1% (95% CI 11.3-37.3). There were no cases of late graft failure (after 100 days), and median whole blood and myeloid donor chimerism of engrafted patients were >95% at all time points. One of the nine patients with early graft failure had autologous reconstitution. The remaining 8 patients underwent repeat HCT; six of the patients survived and achieved durable myeloid engraftment on long-term follow-up. Twenty-eight patients were alive at a median follow-up of 4.28 (IQR 2.66-6.08) years. Estimated 3-year overall and event-free survival were 73.7% (95% CI 56.5-84.9) and 56.2% (95% CI 39.3-70.1), respectively. No identifiable factors, including history of infection or inflammatory disease in the year prior to UCBT, year of UCBT, age at UCBT, conditioning regimen, cell dose, and recipient and donor HLA match, were associated with graft failure or survival. Infections decreased with time post-UCBT and pre-existing inflammatory disease resolved in all surviving patients CONCLUSIONS: UCBT for CGD is associated with high rates of early graft failure. Nevertheless, UCBT can provide an effective alternative for CGD patients when HLA-matched donors are not available with resolution of disease. Strategies to overcome high rates of early graft failure while optimizing conditioning regimens to minimize toxicity are needed.

#3

Case report: a case of CYBB gene variant in X-linked chronic granulomatous disease.

BMC pediatrics2026 Mar 19
#4

A twin with a novel pathogenic variant in CYBB induced X-linked chronic granulomatous disease: a rare case report of misdiagnosis as congenital cystic lung disease.

BMC pediatrics2026 Feb 21
#5

Chronic Granulomatous Disease Presenting with Recurrent Ascites and Primary Peritonitis.

Indian journal of pediatrics2026 Feb

Publicações recentes

Ver todas no PubMed

📚 EuropePMC2.355 artigos no totalmostrando 196

2026

Peripheral Nerve Ultrasound Findings in Leprosy: A Scoping Review of Echogenicity, Cross-Sectional Area, and Vascularization Across 15 Studies.

Clinical, cosmetic and investigational dermatology
2026

Case report: a case of CYBB gene variant in X-linked chronic granulomatous disease.

BMC pediatrics
2026

Chronic granulomatous disease with suspected secondary hemophagocytic lymphohistiocytosis: a case report and hypothesis-generating rationale for neuroimmune modulation.

Critical care (London, England)
2026

The New Wave of Gene and Cell Therapies Across Diseases.

Journal of clinical medicine
2026

Cerebral amebiasis due to Acanthamoeba sp. in a patient with complete gp91 phox deficiency.

Journal of human immunity
2026

Novel indications for hematopoietic stem cell transplantation in inborn errors of immunity.

Expert review of clinical immunology
2026

High-Resolution Ultrasonography for Detecting Peripheral Neuropathy in Leprosy: A Systematic Review and Meta-Analysis.

Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society
2026

Identification of a novel hypomorphic variant in CYBB underlying an adult presentation of X-linked recessive Mendelian susceptibility to mycobacterial disease.

Clinical immunology (Orlando, Fla.)
2026

A Multifactorial Presentation of Infection and Thrombosis: Temporal Clustering of Pneumonia, Hepatic Abscess, Bilateral Deep Vein Thromboses (DVTs), and Appendicitis in a Child.

Cureus
2026

Vertebral Aspergillus Osteomyelitis Mimicking Tuberculosis in an Adolescent With Chronic Granulomatous Disease.

The Pediatric infectious disease journal
2026

Characteristics of monogenic inflammatory bowel disease in very early-onset cases: a Japanese multicenter registry study.

Intestinal research
2026

Colonic Malakoplakia With an Adenomatous Appearance on Magnification Endoscopy: A Case Report.

DEN open
2026

Human infections caused by pathogenic Burkholderia: current clinical challenges and future perspectives.

Infection
2026

A twin with a novel pathogenic variant in CYBB induced X-linked chronic granulomatous disease: a rare case report of misdiagnosis as congenital cystic lung disease.

BMC pediatrics
2026

Optimizing the diagnosis of chronic granulomatous disease using dihydrorhodamine-123 assay: Lessons from a large monocentric cohort.

Cytometry. Part B, Clinical cytometry
2026

Lung microbial dysregulation and TNF inhibition contribute to worsened nontuberculous mycobacterial lung disease.

Research square
2026

Transcatheter Arterial Approach for Refractory Liver Abscesses in Chronic Granulomatous Disease: A Case Series.

Journal of clinical immunology
2026

Research Progress on Chronic Granulomatous Disease in Children.

Cureus
2025

Atopy and immune dysregulation among patients with chronic granulomatous disease.

Frontiers in immunology
2026

Remarkable Rituximab Response in a Chronic Granulomatous Disease Patient on the Verge of a Lung Transplant.

Scandinavian journal of immunology
2026

Chronic Granulomatous Disease: Clinical and Molecular Characterization of Brazilian Patients.

The journal of gene medicine
2026

Misleading presentation of tuberculosis in a child with CGD revealing invasive aspergillosis: A molecularly confirmed case.

IDCases
2026

Neutrophil progenitor cell therapy rescues host defense against Staphylococcus aureus in murine chronic granulomatous disease.

Journal of leukocyte biology
2026

[An adolescent male presenting with fever and pulmonary opacities].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
2025

Phagocyte NADPH Oxidase NOX2-Derived Reactive Oxygen Species in Antimicrobial Defense: Mechanisms, Regulation, and Therapeutic Potential-A Narrative Review.

Antioxidants (Basel, Switzerland)
2025

Unmasking Invasive Pulmonary Aspergillosis: Insights From a Case Series at a Tertiary Care Center.

Cureus
2026

Elevated type I interferon signature in patients with chronic granulomatous disease.

Clinical and experimental immunology
2026

Chronic Granulomatous Disease Presenting with Recurrent Ascites and Primary Peritonitis.

Indian journal of pediatrics
2026

Beyond Fumigatus: a molecular portrait of clinical Aspergillus diversity, pathogenicity, and antifungal resistance.

Antimicrobial agents and chemotherapy
2026

Dysregulation of U12-Type Splicing in Lupus Neutrophils.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2025

Erythema Nodosum Leprosum Triggered by Herpes Simplex Infection: A Case Report.

Cureus
2025

Ulcerative Necrobiosis Lipoidica in the Setting of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma and Glucose-6-Phosphate Dehydrogenase Deficiency.

Cureus
2026

Neonatal-Onset Chronic Granulomatous Disease Presenting With Recurrent Culture-Negative Meningitis: A Case Report and Diagnostic Considerations.

Case reports in immunology
2025

Sarcoidosis Mimicking Metastatic Disease: Multisystem Involvement With Osseous Manifestations.

Cureus
2026

Bladder masses simulating neoplasia in chronic granulomatous disease: Diagnostic challenges and spontaneous regression.

Urology case reports
2025

X-linked chronic granulomatous disease combined with disseminated nontuberculous mycobacteria and fungal infections: Diagnosis and treatment analysis.

Medicine
2025

TYK2 Deficiency Presenting as Refractory Disseminated BCG/Tuberculosis Infection in a Kazakh Child: A Case Report with Genetic Confirmation.

Genes
2025

Incidence, risk factors and outcomes of BCGosis following BCG vaccination in infants: a systematic review and meta-analyses.

Frontiers in immunology
2025

Somatic mosaicism of CYBB causing atypical CGD with inflammatory symptoms.

Immunologic research
2025

Mapping the landscape of autoimmunity and autoinflammation in inborn errors of immunity: broad distribution with distinct clustering patterns.

Frontiers in immunology
2025

Toll-like Receptors in Inborn Errors of Immunity in Children: Diagnostic Potential and Therapeutic Frontiers-A Review of the Latest Data.

Cells
2025

Prime Editing for p47phox-Deficient Chronic Granulomatous Disease.

The New England journal of medicine
2025

Abnormal DHR is not always synonymous with a diagnosis of chronic granulomatous disease.

BMJ case reports
2025

NLRP3 inflammasome blockade treats intestinal inflammation associated with chronic granulomatous disease.

Blood
2026

Comparative volatilomics identifies ubiquitous sulfur compounds inhibiting the fungal pathogen Rasamsonia argillacea.

Microbiology spectrum
2025

An optimized protocol for isolating Rhinosporidium seeberi sporangia from rhinosporidiosis tissue and extracting genomic DNA for next-generation sequencing.

Molecular biology reports
2026

Evaluation of a rapid flow cytometry assay to assess functional engraftment in CGD patients post-transplant and comparison with molecular chimerism.

Journal of immunological methods
2025

Breaking the mold: a case of invasive Medicopsis romeroi pulmonary infection with innovative granulocyte treatment strategy.

ASM case reports
2026

Job's not done: BCG-itis as the first manifestation of hyper-IgE syndrome. A case report and review of the literature.

Clinical immunology (Orlando, Fla.)
2025

Fungal Infections - a Stealthy Enemy in Patients with Chronic Granulomatous Disease: a 28-years' Experience from North India.

Journal of clinical immunology
2025

Consecutive non-Aspergillus Fungal Invasive Infections in Chronic Granulomatous Disease: Data from the French National Reference Center for Primary ImmunoDeficiencies and literature review.

Journal of clinical immunology
2026

Excellent Outcome of 1-Day Nonmyeloablative Salvage Regimen for Pediatric Patients with Graft Failure following Haploidentical Hematopoietic Stem Cell Transplantation.

Transplantation and cellular therapy
2025

Hemophagocytic lymphohistiocytosis in 60 Mexican children with chronic granulomatous disease.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
2025

Chronic Granulomatous Disease in Pregnancy: a Rare Case Report.

Folia medica
2025

Hepatosplenic abscesses in a child with p40phox deficiency due to a homozygous NCF4 variant.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
2025

Nocardia in inborn errors in immunity.

Infectious diseases (London, England)
2025

Recurrent Transfusions and Severe Infections: Unmasking Hatipoglu Immunodeficiency Syndrome: Case Report and Review of Literature.

Journal of pediatric hematology/oncology
2025

Use of dupilumab in eczematous eruptions following hematopoietic cell transplantation.

JAAD case reports
2026

Repurposing sodium glucose cotransporter-2 (SGLT-2) inhibitors in sarcoidosis: A potential strategy for reducing mortality.

Heart &amp; lung : the journal of critical care
2025

Antisense phosphorodiamidate morpholino oligomers retain activity in Burkholderia cepacia complex biofilm.

Frontiers in microbiology
2025

Rasamsonia argillacea brain abscess in a lung transplant recipient: an unexpected infection by an unusual fungal pathogen.

Medical mycology case reports
2026

Umbilical Cord Blood Transplantation Provides an Alternative for Patients With Chronic Granulomatous Disease Lacking HLA-Matched Donors: A PIDTC Report.

Transplantation and cellular therapy
2025

Prime Editing: The Next Frontier in Precision Gene Therapy.

The journal of gene medicine
2025

Five CGD-Linked CYBB Mutations in Chinese Patients: Insights Into Predicting IFN-γ Treatment Efficacy.

Journal of clinical immunology
2025

Thrombocytopenia in patients with inborn errors of immunity.

BMC immunology
2025

Mortality rate and causes of death in inborn errors of immunity: A systematic review and meta-analysis.

Mutation research. Reviews in mutation research
2025

A 10-year-old Girl with an 8-Month History of Progressive Photophobia and Hemeralopia.

Retinal cases &amp; brief reports
2025

Is it time for the A/I (allergist/immunologist) to embrace AI (artificial intelligence) in diagnosis and treatment of the inborn errors of immunity?

Allergy and asthma proceedings
2025

Reliable genetic diagnosis of NCF1 (p47phox)-deficient chronic granulomatous disease using high-throughput sequencing.

Frontiers in immunology
2025

Unmasking chronic granulomatous disease: A routine diagnostic workup in a Brazilian children's hospital.

Allergologia et immunopathologia
2025

Interferon-gamma 1b-induced gene expression alters neutrophil function in patients with chronic granulomatous disease.

PloS one
2025

Clinical, biochemical, and genetic characterization of Lebanese patients with chronic granulomatous disease due to NCF2 pathogenic variants.

Clinical immunology (Orlando, Fla.)
2025

The Nox2 NADPH oxidase regulates neutrophilic inflammation in the oral cavity.

bioRxiv : the preprint server for biology
2026

Importance of BCG Vaccination at birth in Pediatric Patients with Chronic Granulomatous Disease after Hematopoietic Stem Cell Transplantation in Developing Countries.

Immunology letters
2025

Renal Malacoplakia Following Obstetric Intervention: A Rare Cause of Acute Kidney Injury in a Young Woman.

Clinics and practice
2025

A curious case of hypercalcemic crisis in sarcoidosis: The missing link beyond 1,25(OH)2D.

Journal of family medicine and primary care
2025

Targeted gene editing and near-universal cDNA insertion of CYBA and CYBB as a treatment for chronic granulomatous disease.

Nature communications
2025

Hereditary distal renal tubular acidosis with chronic granulomatous disease: a rare coincidence.

CEN case reports
2025

mTORC1-Dependent Regulation of the CCL24-CCR3 Axis Controls Granuloma Formation and Maintenance in Sarcoidosis.

bioRxiv : the preprint server for biology
2025

Isolated Nasolacrimal Duct Rhinosporidiosis - A Rare Presentation of this Enigmatic Disease.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
2025

Longitudinal Meta-cohort study protocol using systems biology to identify vaccine safety biomarkers.

Vaccine
2025

Necrotizing ulcerative stomatitis following bone marrow transplantation in a patient with chronic granulomatous disease: Case report.

Clinical advances in periodontics
2025

Liver Abscess: Think Outside the Box.

Cureus
2025

Recognising Aspergillus udagawae in a child with chronic granulomatous disease.

The Lancet. Infectious diseases
2025

Rheumatologic manifestations in an X-Linked chronic granulomatous disease carrier.

The American journal of the medical sciences
2025

Hyper-IgE syndrome: A rare case report.

The journal of allergy and clinical immunology. Global
2025

Interferon gamma rebalances immunopathological signatures in chronic granulomatous disease through metabolic rewiring.

Blood advances
2025

Invasive Mould Infections in Chronic Granulomatous Disease: A Multicenter Study From Türkiye.

Mycoses
2025

Early diagnosis of chronic granulomatous disease and McLeod syndrome via the use of a next generation sequencing.

Pediatrics international : official journal of the Japan Pediatric Society
2025

Dysregulated Pro-inflammatory and Anti-inflammatory Cytokine Responses to Microbe-associated Molecular Patterns in X-linked Chronic Granulomatous Disease.

In vivo (Athens, Greece)
2025

Malakoplakia in kidney transplant recipients: Three case reports.

World journal of nephrology
2025

Characterizing neonatal community-acquired invasive fungal infections: Clinical profiles, pathogens, and underlying conditions.

Medicine
2025

The value of DHR-enzyme-linked immunosorbent assay in the diagnosis of chronic granulomatous disease by detecting NADPH oxidase complex activity.

Frontiers in pediatrics
2025

Primary Gastrointestinal Iatrogenic Kaposi Sarcoma: A Rare Pediatric Case Report.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
2025

Clinical characteristics and genetic features of 35 cases of adverse reactions to Bacillus Calmette-Guérin vaccine in children.

Frontiers in cellular and infection microbiology
2025

Genetic Variants in Early-Onset Inflammatory Bowel Disease: Monogenic Causes and Clinical Implications.

Children (Basel, Switzerland)
2025

Postinfectious manifestations in two pediatric female X-linked carriers of chronic granulomatous disease.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
2025

Clinical manifestations of 42 Moroccan patients with chronic granulomatous disease.

Qatar medical journal
2025

Decreased neutrophil oxidative burst activity in children with failure to thrive - a pilot study.

American journal of blood research
2025

Bridging to Transplant: TDM-guided Outpatient Dalbavancin Therapy in Chronic Granulomatous Disease With Deep-seeded Inoperable Abscesses Over 11 Months.

Open forum infectious diseases
2025

Skin Manifestations in Adults With Chronic Granulomatous Disease in the United Kingdom.

The journal of allergy and clinical immunology. In practice
2025

Chronic granulomatous disease: lessons in cell biology from monogenic immunodeficiency.

Clinical and experimental immunology
2025

Evaluation of the Etiology of Granulomatous Lymphadenopathy in Children Admitted to a Tertiary Pediatric Infectious Clinic.

Turkish archives of pediatrics
2025

Conjunctival Rhinosporidosis Mimicking Papilloma in an Ethiopian Child: A Rare Case Report.

Clinical case reports
2025

De novo DUOX2 expression in neutrophil subsets shapes the pathogenesis of intestinal disease.

Proceedings of the National Academy of Sciences of the United States of America
2025

Incidence of nasal rhinosporidiosis in the UK.

BMJ case reports
2025

Dried blood spot proteome identifies subclinical interferon signature in neonates with type I interferonopathy.

The Journal of allergy and clinical immunology
2025

Non-Infectious Complications of Chronic Granulomatous Disease: Knowledge Gaps & Novel Treatment Considerations.

Immunology and allergy clinics of North America
2025

Invasive Fungal Infection by Scedosporium apiospermum with Cerebral Involvement in a Pediatric Patient Affected by Chronic Granulomatous Disease After Hematopoietic Cell Transplant.

Journal of fungi (Basel, Switzerland)
2025

Single-cell and spatial transcriptomics reveal the pathogenesis of chronic granulomatous disease in a natural model.

Cell reports
2025

Hematopoietic Cell Transplantation in a Patient With X-Linked Chronic Granulomatous Disease With McLeod Phenotype.

Pediatric transplantation
2025

Genotype-specific immune responses at the intestinal barrier predispose to colitis in mouse models of chronic granulomatous disease.

Blood
2025

The Role of NADPH Oxidase 2 in Leukocytes.

Antioxidants (Basel, Switzerland)
2025

Pediatric rhinoscleroma of the nasal cavity: A case report and review of literature.

International journal of surgery case reports
2025

Burkholderia cenocepacia-mediated inhibition of Staphylococcus aureus growth and biofilm formation.

Journal of bacteriology
2025

Pediatric Presentations of Granulomatosis With Polyangiitis: A Double Case Study.

Case reports in dermatological medicine
2025

[Infectious pulmonary artery pseudoaneurysms in 3 children and literatures review].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2025

HLA-haploidentical stem cell transplantation for chronic granulomatous disease: an EBMT-IEWP retrospective study.

Blood
2025

Inborn errors of immunity in Canadian First Nations and Nunavut Inuit Children: the tip of the iceberg.

Paediatrics &amp; child health
2025

Gene therapy for inborn errors of immunity: Current clinical progress.

Annals of allergy, asthma &amp; immunology : official publication of the American College of Allergy, Asthma, &amp; Immunology
2025

Clinical significance and antifungal susceptibility profile of 103 clinical isolates of Scedosporium species complex and Lomentospora prolificans obtained from NIH patients.

Journal of clinical microbiology
2024

First case of invasive Rasamsonia argillacea in a child with chronic granulomatous disease in Qatar.

Medical mycology case reports
2025

Tuberculosis Presenting as a Patchy Consolidation in a Young Patient With Chronic Granulomatosis Disease.

Clinical case reports
2025

Tackling Infectious Diseases in the Caribbean and South America: Epidemiological Insights, Antibiotic Resistance, Associated Infectious Diseases in Immunological Disorders, Global Infection Response, and Experimental Anti-Idiotypic Vaccine Candidates Against Microorganisms of Public Health Importance.

Microorganisms
2025

X-Linked CGD Chorioretinitis in Two Young Girls.

Biomedicines
2025

Treatment of Post-COVID-19 Pulmonary Aspergilloma: Insights from a Clinical Case.

The American journal of case reports
2025

Management of sporotrichosis in patients with inflammatory bowel disease using biological therapy (antitumor necrosis factor).

European journal of gastroenterology &amp; hepatology
2025

A Case of Gaucher Disease With Atypical Presentation Mimicking Chronic Recurrent Multifocal Osteomyelitis.

Cureus
2025

Reactive oxygen species regulate early development of the intestinal macrophage-microbiome interface.

Blood
2025

Functional assays for the diagnosis of chronic granulomatous disease.

Journal of immunological methods
2025

Viral-based gene therapy clinical trials for immune deficiencies and blood disorders from 2013 until 2023 - an overview.

Regenerative therapy
2025

Misdiagnosis of Leprosy with Severe Reversal Reaction as Psoriatic Arthritis: A Case Report and Literature Review.

Clinical, cosmetic and investigational dermatology
2024

Standardization of the use of opsonized zymosan as stimulus in the 1,2,3-dihydrorhodamine technique for the assessment of neutrophil respiratory burst.

Biomedica : revista del Instituto Nacional de Salud
2024

Four-month-old infant with chronic granulomatous disease and invasive aspergillosis with bone involvement.

Biomedica : revista del Instituto Nacional de Salud
2024

Clinical and genetic description of patients with chronic granulomatous disease in a pediatric hospital.

Biomedica : revista del Instituto Nacional de Salud
2025

Chitosan/γ-PGA nanoparticles and IFN-γ immunotherapy: A dual approach for triple-negative breast cancer treatment.

Journal of controlled release : official journal of the Controlled Release Society
2024

Pancreatic Sarcoidosis: A Rare Manifestation of Systemic Sarcoidosis.

Cureus
2025

Epidemiology, risk factors, and awareness of mycetoma among residents in Eastern Sinnar locality, Sudan, 2021.

Journal of global health
2024

An Adult-Onset Chronic Granulomatous Disease Case with Hemophagocytic Lymphohistiocytosis Caused by Burkholderia and Aspergillus Infections.

Infectious diseases &amp; clinical microbiology
2025

A case report: Endobronchial ultrasound guided biopsy of radiographically normal size thoracic lymph nodes supporting diagnosis of cardiac sarcoidosis.

Respiratory medicine case reports
2025

Implementation of a Pilot Study in Adolescent Health Care Transition Program for Chronic Granulomatous Disease: A Single Institution Experience.

Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates &amp; Practitioners
2024

Mulch pneumonitis in chronic granulomatous disease: More than just a fungal infection.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
2024

Neonatal Chronic Granulomatous Disease With Septic Arthritis and Osteomyelitis: Diagnostic and Therapeutic Challenge With Literature Review.

Journal of investigative medicine high impact case reports
2024

A Rare Case of Nasal Rhinosporidiosis in the Santhal Pargana Region of Jharkhand: Clinical Presentation and Management.

Cureus
2024

Case report: Candida blankii osteo-articular infection in a patient with Chronic Granulomatous Disease.

Medical mycology case reports
2024

Etiology, Clinical Profile and Factors Predicting Disease Recurrence of Rhinosporidiosis in a Tertiary Care Centre in Kanyakumari District.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
2024

Characterization and Comparative Genomic Analysis of vB_BceM_CEP1: A Novel Temperate Bacteriophage Infecting Burkholderia cepacia Complex.

Journal of microbiology (Seoul, Korea)
2024

Competency of Jeffrey Modell Foundation warning signs and routine laboratory tests in suspecting primary immunodeficiencies: A cross-sectional multi-centric prospective study from eastern India.

International journal of rheumatic diseases
2024

Two distinct clinical progressions of P67phox-deficient CGD, both commencing with cervical lymphadenitis.

Italian journal of pediatrics
2025

Outcomes in hematopoetic cell transplantation in the setting of mold infections in patients with chronic granulomatous disease.

Bone marrow transplantation
2025

Mold infections in chronic granulomatous disease patients-what comes to the rescue?

Bone marrow transplantation
2024

Primary actinomycotic osteomyelitis of metacarpal bones managed successfully with surgical debridement and Welsh regimen.

BMJ case reports
2024

NOX2 deficiency promotes GSDME-related pyroptosis by reducing AMPK activation in neutrophils.

International immunopharmacology
2024

Long-Term Observation of Focal Segmental Glomerulosclerosis after Treatment of Renal Parenchymal Malakoplakia: A Case Report.

Case reports in nephrology and dialysis
2024

Histoplasma capsulatum Infection With Both Granulomatous Features and Fibrosing Mediastinitis Presenting as Shortness of Breath: A Case Report.

Cureus
2024

Tropicoporus tropicalis: A Newly Recognised Pathogen in Eumycetoma and Refractory Mycoses in Humans.

Mycoses
2025

Chest Wall CT-Fistulography for Surgical Planning in a Patient With Chronic Granulomatous Disease.

Archivos de bronconeumologia
2024

Novel hypomorphic CYBB variant causing chronic granulomatous disease with incomplete penetrance.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
2024

High-fidelity PAMless base editing of hematopoietic stem cells to treat chronic granulomatous disease.

Science translational medicine
2024

Gene editing of NCF1 loci is associated with homologous recombination and chromosomal rearrangements.

Communications biology
2024

Severe clinical phenotypes of heterozygous females with X-linked chronic granulomatous disease.

The journal of allergy and clinical immunology. In practice
2024

Hematopoietic cell transplantation for inborn errors of immunity: an update on approaches, outcomes and innovations.

Current opinion in pediatrics
2024

Chronic Granulomatous Disease as Differential Diagnosis to Crohn's Disease in Children: a Case Report.

Acta dermato-venereologica
2024

Immunodeficiency: Gene therapy for primary immune deficiency.

Allergy and asthma proceedings
2024

A Rare Case of Isolated Extrapulmonary Sarcoidosis With Renal Involvement Sans Pulmonary Findings: Diagnostic Challenges and Clinical Insights.

Cureus
2024

High symptom burden in female X-linked chronic granulomatous disease carriers.

Clinical immunology (Orlando, Fla.)
2024

Inborn errors of immunity and invasive fungal infections: presentation and management.

Current opinion in infectious diseases
2025

Dihydrorhodamine-123 flow cytometry method: time for substantial revision in technical procedure.

Laboratory medicine
2024

Imaging of Madura foot: Case report.

Radiology case reports
2024

A Rare Case of Tubercular Osteomyelitis of Mandible in a 5-year-old Child.

International journal of clinical pediatric dentistry
2024

Profile of juvenile systemic lupus erythematosus patients with a special reference to monogenic lupus and lupus nephritis: a cross-sectional study.

Rheumatology international
2024

Permissive lung neutrophils facilitate tuberculosis immunopathogenesis in male phagocyte NADPH oxidase-deficient mice.

PLoS pathogens
2024

Rheumatoid arthritis complicated with cervical actinomycosis and ureteral obstruction: A case report and literature review.

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
2024

Expanding the Clinical Phenotype of Autosomal Recessive Chronic Granulomatous Disease.

Journal of clinical immunology
2024

Diagnosis of Chronic Granulomatous Disease: Strengths and Challenges in the Genomic Era.

Journal of clinical medicine
2024

Burkholderia cepacia Complex Producing a Peculiar Violet Pigment: A Case Series From a Tertiary Care Hospital in Meghalaya.

Cureus
2024

A Case of Chronic Granulomatous Disease Masquerading As Tubercular Lymphadenitis in an Infant.

Cureus
2024

Description of BCG and Tuberculosis Disease in a Cohort of 79 Patients with Chronic Granulomatous Disease.

Journal of clinical immunology
2024

Spontaneous NETosis and type I IFN signaling activation in resting neutrophils of chronic granulomatous disease patients with CYBB mutations.

Genes &amp; diseases
2024

[Chest computed tomography manifestations in neonates with chronic granulomatous disease].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
2024

Clinical presentation, diagnosis, and treatment of chronic granulomatous disease.

Frontiers in pediatrics
2024

A rare differential diagnosis of inflammatory bowel disease in a young male patient; a challenging case report.

Gastroenterology and hepatology from bed to bench
2024

Nonendemic rhinoscleroma: An unusual manifestation of the trachea.

Laryngoscope investigative otolaryngology
2024

Self-extinguishing relay waves enable homeostatic control of human neutrophil swarming.

Developmental cell
2024

Cutaneous Inflammatory Manifestations of Chronic Granulomatous Disease.

JAMA dermatology
2024

Novel infantile presentations of chronic granulomatous disease.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
2024

Targeted knock-in of NCF1 cDNA into the NCF2 locus leads to myeloid phenotypic correction of p47 phox -deficient chronic granulomatous disease.

Molecular therapy. Nucleic acids
2024

A Mouse Model of X-Linked Chronic Granulomatous Disease for the Development of CRISPR/Cas9 Gene Therapy.

Genes
2024

Air pollution and incident sarcoidosis in central Pennsylvania.

Journal of toxicology and environmental health. Part A
2025

Chronic granulomatous disease: A single-center experience in Central Anatolia.

Pediatrics and neonatology
2024

Genotype-phenotype correlations in chronic granulomatous disease: insights from a large national cohort.

Blood
2024

First Report on Chronic Granulomatous Disease from Nepal and a Review of CYBC1 Deficiency.

Journal of clinical immunology
2024

Case report: A rare case of malacoplakia resembling a malignant tumor of the cervix: a case report and review of the literature.

Frontiers in medicine
2024

Disseminated rhinosporidial osteomyelitis: A rare case report.

Indian journal of pathology &amp; microbiology
2025

BCGosis with erythema nodosum in a child with chronic granulomatous disease: An atypical presentation.

Indian journal of dermatology, venereology and leprology
2024

Chronic Granulomatous Disease: A Rare Primary Immunodeficiency Disorder in Pakistan due to Under-diagnosis or Under-prevalence?

Journal of pediatric surgery
Ver todos os 2.355 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença granulomatosa crônica.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Doença granulomatosa crônica e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

É uma imunodeficiência primária rara que prejudica a atuação dos fagócitos na destruição de microrganismos invasores. Os pacientes apresentam infecções repetidas por bactérias e fungos e desenvolvem áreas de inflamação tecidual chamadas granulomas.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

10 publicações do grafo RarasNet (PubMed) · 7 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. ORPHA:379
    Orphanet
  2. GARD:6100
    GARD (NIH)
  3. Q2165663
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Doença granulomatosa crônica. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/doenca-granulomatosa-cronica

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Doença granulomatosa crônica

ORPHA:379 · MONDO:0018305
Prevalência
1-9 / 1 000 000
Herança
Autosomal recessive, X-linked recessive
CID-10
D71 · Transtornos funcionais dos neutrófilos polimorfonucleares
CID-11
Ensaios
23 ativos
Início
Adolescent, Adult, Childhood, Infancy
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0018203
EuropePMC
Wikidata
Wikipedia
Papers 10a

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata
Medicamentos aprovados FDA
fonte: FDA OpenFDA
Rara